Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go

New Merck Debt Totals $8bn; ImmunoGen Raises $297.5m

Executive Summary

Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.

You may also be interested in...



Finance Watch: Five More Small IPOs Squeeze Through The US Window

Public Company Edition: Genenta, Cingulate, ImmixBio, Bionomics and NeuroSense launched initial public offerings, grossing just $118m between them. But Amylyx, with a recently filed ALS drug, has filed to raise up to $100m. In follow-on offerings, Legend took advantage of ASH goodwill to raise $300m. 

BeiGene Switches To Combo Therapy Approach For Brukinsa

BeiGene exec reveals Chinese firm's changing development strategy around key asset as further clinical results emerge.

BenevolentAI Goes Public In Europe’s Largest SPAC

The UK computational medicines specialist is listing on the Euronext Amsterdam after linking up with healthcare-focused special purpose acquisition corporation Odyssey which is advised by former Sanofi CEO Olivier Brandicourt.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel